G1 THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.3 USD | -0.30% |
|
-19.32% | +8.20% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 993.3 | 684.4 | 434.2 | 274.8 | 158.1 | 172.5 | - | - |
| Enterprise Value (EV) 1 | 724.1 | 684.4 | 434.2 | 274.8 | 158.1 | 172.5 | 172.5 | -2,402 |
| P/E ratio | -8.08 x | -6.87 x | -2.88 x | -1.61 x | -3.28 x | -6.06 x | -11 x | 0.84 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 15.1 x | 13.8 x | 5.36 x | 1.92 x | 2.43 x | 1.81 x | 0.5 x |
| EV / Revenue | - | 15.1 x | 13.8 x | 5.36 x | 1.92 x | 2.43 x | 1.81 x | 0.5 x |
| EV / EBITDA | -7.72 x | -7.14 x | -3.06 x | -2.03 x | -4.05 x | -6.51 x | -9.86 x | 0.36 x |
| EV / FCF | -9.71 x | -8.17 x | -3.29 x | - | -4.12 x | 24.6 x | 7.19 x | 0.18 x |
| FCF Yield | -10.3% | -12.2% | -30.4% | - | -24.2% | 4.06% | 13.9% | 559% |
| Price to Book | 3.89 x | 3.87 x | 3.03 x | - | 4.46 x | 7.7 x | 1.51 x | 0.06 x |
| Nbr of stocks (in thousands) | 37,582 | 38,046 | 42,522 | 50,612 | 51,844 | 52,281 | - | - |
| Reference price 2 | 26.43 | 17.99 | 10.21 | 5.430 | 3.050 | 3.300 | 3.300 | 3.300 |
| Announcement Date | 2/26/20 | 2/24/21 | 2/23/22 | 3/1/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 45.28 | 31.48 | 51.3 | 82.51 | 70.95 | 95.42 | 345.6 |
| EBITDA 1 | -128.7 | -95.89 | -142 | -135.6 | -39.01 | -26.5 | -17.5 | 478.8 |
| EBIT 1 | -129 | -96.48 | -142.5 | -136.2 | -39.53 | -27.82 | -19.8 | 187.5 |
| Operating Margin | - | -213.04% | -452.59% | -265.45% | -47.91% | -39.21% | -20.74% | 54.24% |
| Earnings before Tax (EBT) 1 | -122.4 | -97.84 | -147.4 | -145.9 | -44.85 | -31.08 | -21.48 | 186.6 |
| Net income 1 | -122.4 | -99.25 | -148.4 | -147.6 | -47.97 | -31.15 | -21.41 | 186.6 |
| Net margin | - | -219.18% | -471.32% | -287.63% | -58.13% | -43.91% | -22.43% | 53.99% |
| EPS 2 | -3.270 | -2.620 | -3.540 | -3.380 | -0.9300 | -0.5448 | -0.2999 | 3.936 |
| Free Cash Flow 1 | -102.3 | -83.74 | -132.1 | - | -38.34 | 7 | 24 | 965 |
| FCF margin | - | -184.92% | -419.71% | - | -46.46% | 9.87% | 25.15% | 279.23% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 201.56% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 517.22% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 2/24/21 | 2/23/22 | 3/1/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.796 | 6.902 | 10.57 | 23.58 | 10.25 | 12.95 | 42.39 | 12.3 | 14.87 | 14.48 | 16.03 | 17.26 | 23.18 | 18.85 | 20.4 |
| EBITDA 1 | -37.47 | -46.67 | -36.82 | -21.41 | -30.75 | -25.61 | 11.65 | -16.24 | -8.805 | -8.928 | -8 | -7.5 | -1.5 | -4 | -2 |
| EBIT 1 | -37.59 | -46.78 | -36.96 | -21.55 | -30.89 | -25.75 | 11.52 | -16.37 | -8.929 | -9.048 | -7.984 | -7.426 | -3.256 | -4.915 | -2.097 |
| Operating Margin | -648.48% | -677.79% | -349.59% | -91.4% | -301.34% | -198.87% | 27.17% | -133.07% | -60.03% | -62.5% | -49.81% | -43.02% | -14.04% | -26.07% | -10.28% |
| Earnings before Tax (EBT) 1 | -39.77 | -49.19 | -39.45 | -24.05 | -33.17 | -27.6 | 10.02 | -17.3 | -9.976 | -10.22 | -8.876 | -8.298 | -3.896 | -5.415 | -2.597 |
| Net income 1 | -40.02 | -49.19 | -39.45 | -25.27 | -33.65 | -27.6 | 8.71 | -18.2 | -10.88 | -10.22 | -8.877 | -8.297 | -3.896 | -5.414 | -2.596 |
| Net margin | -690.48% | -712.72% | -373.08% | -107.19% | -328.28% | -213.15% | 20.55% | -148% | -73.14% | -70.59% | -55.39% | -48.07% | -16.8% | -28.72% | -12.73% |
| EPS 2 | -0.9400 | -1.150 | -0.9200 | -0.5900 | -0.7300 | -0.5300 | 0.1400 | -0.3500 | -0.2100 | -0.2000 | -0.1674 | -0.1356 | -0.0583 | -0.1100 | -0.0700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/23/22 | 5/4/22 | 8/3/22 | 11/2/22 | 3/1/23 | 5/3/23 | 8/2/23 | 11/1/23 | 2/28/24 | 5/1/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 269 | - | - | - | - | - | - | 2,575 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -102 | -83.7 | -132 | - | -38.3 | 7 | 24 | 965 |
| ROE (net income / shareholders' equity) | -39.9% | -45.9% | -92.5% | -139% | -92.1% | -125% | -20.4% | 67.5% |
| ROA (Net income/ Total Assets) | -37.3% | -38.7% | -61.5% | -66.8% | -31% | -35.3% | -14.5% | 66.5% |
| Assets 1 | 328.1 | 256.7 | 241.3 | 221 | 154.8 | 88.34 | 147.5 | 280.7 |
| Book Value Per Share 2 | 6.790 | 4.650 | 3.370 | - | 0.6800 | 0.4300 | 2.180 | 53.60 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 2.72 | - | - | - | - | 0.13 | 0.17 | 0.83 |
| Capex / Sales | - | - | - | - | - | 0.18% | 0.17% | 0.24% |
| Announcement Date | 2/26/20 | 2/24/21 | 2/23/22 | 3/1/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.3
USD
Average target price
8.5
USD
Spread / Average Target
+157.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.20% | 173M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- GTHX Stock
- Financials G1 Therapeutics, Inc.
